William Blair initiates MedImmune coverage at outperform

MedImmune Inc. coverage was initiated at an outperform rating by William Blair & Co. analyst John Sonnier, who said the company has a strong late-stage product pipeline. Four marketed drugs and 12 clinical candidates, four of which are in phase III or higher, will drive visibility over the coming year. Shares of the Gaithersburg, Md., biotechnology company were down $0.01, or 0.03%, at $34.93 on volume of 1,912,476 shares versus the three-month running average of 2,843,060 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.